BioStock: BioInvent’s oncolytic virus showcased at ESMO
At the 2025 ESMO Annual Meeting, BioInvent and Transgene presented new and encouraging clinical data for the oncolytic virus candidate BT-001. The results suggest that the therapy could offer a new option for patients with advanced cancers who no longer respond to standard treatments. BT-001 is being evaluated both as a monotherapy and in combination with Keytruda.
Read the full interview at biostock.se:
BioInvent's oncolytic virus presented at ESMO
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/